Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
Identifieur interne : 002621 ( Main/Exploration ); précédent : 002620; suivant : 002622Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
Auteurs : Robert A. Hauser [États-Unis] ; Lisa M. Shulman [États-Unis] ; Joel M. Trugman [États-Unis] ; John W. Roberts [États-Unis] ; Akihisa Mori [Japon] ; Rocco Ballerini [États-Unis] ; Neil M. Sussman [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2008-11-15.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Aged, Analysis of Variance, Antiparkinson Agents (therapeutic use), Double-Blind Method, Drug-Related Side Effects and Adverse Reactions, Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (etiology), Female, Fluctuations, Human, Humans, Istradefylline, KW‐6002, Levodopa, Levodopa (adverse effects), Male, Middle Aged, Nervous system diseases, Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson disease, Parkinson's disease, Purines (therapeutic use), Questionnaires, Severity of Illness Index, Time Factors, Treatment, istradefylline, motor fluctuations, off time, treatment.
- MESH :
- chemical , adverse effects : Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Purines.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced.
- physiopathology : Parkinson Disease.
- Aged, Analysis of Variance, Double-Blind Method, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Male, Middle Aged, Questionnaires, Severity of Illness Index, Time Factors.
Abstract
The objective of this study was to evaluate the efficacy, safety, and tolerability of istradefylline 20 mg once daily versus placebo as an adjunct to levodopa in subjects with Parkinson's disease (PD) who have motor fluctuations. Istradefylline (KW‐6002) is an adenosine A2A receptor antagonist that in primate models of PD improves motor function without causing or worsening dyskinesia. This 12‐week, multicenter, double‐blind, placebo‐controlled, randomized, Phase 3 study of istradefylline was conducted in subjects experiencing an average daily OFF time of at least 3 hours (116 randomized to istradefylline; 115 to placebo). All were on stable levodopa regimens; 90% were also on stable regimens of other anti‐Parkinson's medications. Istradefylline‐treated subjects had significant placebo‐corrected reductions in daily OFF time from baseline to endpoint: 4.6% (P = 0.03) and 0.7 hours (P = 0.03). For ON time with troublesome dyskinesia, the changes between istradefylline and placebo were not significant. Istradefylline was well tolerated, with 6 (5.2%) istradefylline‐treated and 7 (6.1%) placebo‐treated subjects withdrawing from the study because of adverse events. Dyskinesia, lightheadedness, tremor, constipation, and weight decrease were reported more often with istradefylline than placebo. We conclude that istradefylline is well tolerated and significantly reduces OFF time as an adjunct to levodopa in PD subjects with motor fluctuations. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22095
Affiliations:
- Japon, États-Unis
- Floride, Maryland, New Jersey, Virginie, Washington (État)
- Tampa
- Université de Floride du Sud
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000D47
- to stream Istex, to step Curation: 000D47
- to stream Istex, to step Checkpoint: 001177
- to stream PubMed, to step Corpus: 001F96
- to stream PubMed, to step Curation: 001F96
- to stream PubMed, to step Checkpoint: 002076
- to stream Ncbi, to step Merge: 002367
- to stream Ncbi, to step Curation: 002367
- to stream Ncbi, to step Checkpoint: 002367
- to stream Main, to step Merge: 003199
- to stream PascalFrancis, to step Corpus: 001051
- to stream PascalFrancis, to step Curation: 001C68
- to stream PascalFrancis, to step Checkpoint: 001086
- to stream Main, to step Merge: 003694
- to stream Main, to step Curation: 002621
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
<author><name sortKey="Shulman, Lisa M" sort="Shulman, Lisa M" uniqKey="Shulman L" first="Lisa M." last="Shulman">Lisa M. Shulman</name>
</author>
<author><name sortKey="Trugman, Joel M" sort="Trugman, Joel M" uniqKey="Trugman J" first="Joel M." last="Trugman">Joel M. Trugman</name>
</author>
<author><name sortKey="Roberts, John W" sort="Roberts, John W" uniqKey="Roberts J" first="John W." last="Roberts">John W. Roberts</name>
</author>
<author><name sortKey="Mori, Akihisa" sort="Mori, Akihisa" uniqKey="Mori A" first="Akihisa" last="Mori">Akihisa Mori</name>
</author>
<author><name sortKey="Ballerini, Rocco" sort="Ballerini, Rocco" uniqKey="Ballerini R" first="Rocco" last="Ballerini">Rocco Ballerini</name>
</author>
<author><name sortKey="Sussman, Neil M" sort="Sussman, Neil M" uniqKey="Sussman N" first="Neil M." last="Sussman">Neil M. Sussman</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D16EBA1B882CDB4F40CD3FAF655B95EF7EB56DD4</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1002/mds.22095</idno>
<idno type="url">https://api.istex.fr/document/D16EBA1B882CDB4F40CD3FAF655B95EF7EB56DD4/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000D47</idno>
<idno type="wicri:Area/Istex/Curation">000D47</idno>
<idno type="wicri:Area/Istex/Checkpoint">001177</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Hauser R:study:of:istradefylline</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:18831530</idno>
<idno type="wicri:Area/PubMed/Corpus">001F96</idno>
<idno type="wicri:Area/PubMed/Curation">001F96</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002076</idno>
<idno type="wicri:Area/Ncbi/Merge">002367</idno>
<idno type="wicri:Area/Ncbi/Curation">002367</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002367</idno>
<idno type="wicri:Area/Main/Merge">003199</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:09-0038007</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001051</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001C68</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001086</idno>
<idno type="wicri:doubleKey">0885-3185:2008:Hauser R:study:of:istradefylline</idno>
<idno type="wicri:Area/Main/Merge">003694</idno>
<idno type="wicri:Area/Main/Curation">002621</idno>
<idno type="wicri:Area/Main/Exploration">002621</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations</title>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Neurology, Molecular Pharmacology, and Physiology, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Shulman, Lisa M" sort="Shulman, Lisa M" uniqKey="Shulman L" first="Lisa M." last="Shulman">Lisa M. Shulman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Maryland School of Medicine, Baltimore, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Trugman, Joel M" sort="Trugman, Joel M" uniqKey="Trugman J" first="Joel M." last="Trugman">Joel M. Trugman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Virginia, Charlottesville, Virginia</wicri:regionArea>
<placeName><region type="state">Virginie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Roberts, John W" sort="Roberts, John W" uniqKey="Roberts J" first="John W." last="Roberts">John W. Roberts</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Section of Neurology, Virginia Mason Medical Center, Seattle, Washington</wicri:regionArea>
<placeName><region type="state">Washington (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mori, Akihisa" sort="Mori, Akihisa" uniqKey="Mori A" first="Akihisa" last="Mori">Akihisa Mori</name>
<affiliation wicri:level="1"><country xml:lang="fr">Japon</country>
<wicri:regionArea>Kyowa Hakko Kogyo Co., Ltd. Tokyo</wicri:regionArea>
<wicri:noRegion>Ltd. Tokyo</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ballerini, Rocco" sort="Ballerini, Rocco" uniqKey="Ballerini R" first="Rocco" last="Ballerini">Rocco Ballerini</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Kyowa Pharmaceutical, Inc., Princeton, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sussman, Neil M" sort="Sussman, Neil M" uniqKey="Sussman N" first="Neil M." last="Sussman">Neil M. Sussman</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Kyowa Pharmaceutical, Inc., Princeton, New Jersey</wicri:regionArea>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2008-11-15">2008-11-15</date>
<biblScope unit="vol">23</biblScope>
<biblScope unit="issue">15</biblScope>
<biblScope unit="page" from="2177">2177</biblScope>
<biblScope unit="page" to="2185">2185</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">D16EBA1B882CDB4F40CD3FAF655B95EF7EB56DD4</idno>
<idno type="DOI">10.1002/mds.22095</idno>
<idno type="ArticleID">MDS22095</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Analysis of Variance</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Dyskinesia, Drug-Induced (drug therapy)</term>
<term>Dyskinesia, Drug-Induced (etiology)</term>
<term>Female</term>
<term>Fluctuations</term>
<term>Human</term>
<term>Humans</term>
<term>Istradefylline</term>
<term>KW‐6002</term>
<term>Levodopa</term>
<term>Levodopa (adverse effects)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Purines (therapeutic use)</term>
<term>Questionnaires</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
<term>Treatment</term>
<term>istradefylline</term>
<term>motor fluctuations</term>
<term>off time</term>
<term>treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Purines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Analysis of Variance</term>
<term>Double-Blind Method</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Questionnaires</term>
<term>Severity of Illness Index</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Fluctuation</term>
<term>Homme</term>
<term>Istradéfylline</term>
<term>Lévodopa</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objective of this study was to evaluate the efficacy, safety, and tolerability of istradefylline 20 mg once daily versus placebo as an adjunct to levodopa in subjects with Parkinson's disease (PD) who have motor fluctuations. Istradefylline (KW‐6002) is an adenosine A2A receptor antagonist that in primate models of PD improves motor function without causing or worsening dyskinesia. This 12‐week, multicenter, double‐blind, placebo‐controlled, randomized, Phase 3 study of istradefylline was conducted in subjects experiencing an average daily OFF time of at least 3 hours (116 randomized to istradefylline; 115 to placebo). All were on stable levodopa regimens; 90% were also on stable regimens of other anti‐Parkinson's medications. Istradefylline‐treated subjects had significant placebo‐corrected reductions in daily OFF time from baseline to endpoint: 4.6% (P = 0.03) and 0.7 hours (P = 0.03). For ON time with troublesome dyskinesia, the changes between istradefylline and placebo were not significant. Istradefylline was well tolerated, with 6 (5.2%) istradefylline‐treated and 7 (6.1%) placebo‐treated subjects withdrawing from the study because of adverse events. Dyskinesia, lightheadedness, tremor, constipation, and weight decrease were reported more often with istradefylline than placebo. We conclude that istradefylline is well tolerated and significantly reduces OFF time as an adjunct to levodopa in PD subjects with motor fluctuations. © 2008 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Japon</li>
<li>États-Unis</li>
</country>
<region><li>Floride</li>
<li>Maryland</li>
<li>New Jersey</li>
<li>Virginie</li>
<li>Washington (État)</li>
</region>
<settlement><li>Tampa</li>
</settlement>
<orgName><li>Université de Floride du Sud</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Floride"><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</region>
<name sortKey="Ballerini, Rocco" sort="Ballerini, Rocco" uniqKey="Ballerini R" first="Rocco" last="Ballerini">Rocco Ballerini</name>
<name sortKey="Roberts, John W" sort="Roberts, John W" uniqKey="Roberts J" first="John W." last="Roberts">John W. Roberts</name>
<name sortKey="Shulman, Lisa M" sort="Shulman, Lisa M" uniqKey="Shulman L" first="Lisa M." last="Shulman">Lisa M. Shulman</name>
<name sortKey="Sussman, Neil M" sort="Sussman, Neil M" uniqKey="Sussman N" first="Neil M." last="Sussman">Neil M. Sussman</name>
<name sortKey="Trugman, Joel M" sort="Trugman, Joel M" uniqKey="Trugman J" first="Joel M." last="Trugman">Joel M. Trugman</name>
</country>
<country name="Japon"><noRegion><name sortKey="Mori, Akihisa" sort="Mori, Akihisa" uniqKey="Mori A" first="Akihisa" last="Mori">Akihisa Mori</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002621 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002621 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:D16EBA1B882CDB4F40CD3FAF655B95EF7EB56DD4 |texte= Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations }}
This area was generated with Dilib version V0.6.23. |